Prasugrel

證據等級: L5

預測適應症: 10 個

Prasugrel: From Antiplatelet Therapy to Pulmonary Hypertension

One-Sentence Summary

Prasugrel is a thienopyridine P2Y12 receptor inhibitor (antiplatelet agent); detailed original indication and MOA data are not available in the current evidence pack. The TxGNN model predicts it may be effective for Pulmonary Hypertension, but the supporting evidence is limited to 2 clinical trials and 2 publications, none of which directly address prasugrel or pulmonary hypertension — this is a high-score, low-evidence signal.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (drug not marketed in Norway; classified as a thienopyridine P2Y12 inhibitor / antiplatelet agent based on literature evidence)
Predicted New Indication	Pulmonary Hypertension
TxGNN Prediction Score	99.88%
Evidence Level	L5 (model prediction only)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (original_moa: [Data Gap]). Based on information embedded in the evidence pack's literature notes, prasugrel is a thienopyridine-class P2Y12 receptor inhibitor, in the same pharmacological family as clopidogrel and ticlopidine, and its established role is as an antiplatelet agent (e.g., for stent thrombosis prevention).

For the top-ranked predicted indication, pulmonary hypertension, the model's own repurposing rationale is explicit about the weakness of the link: "No direct mechanistic connection. Antiplatelet drugs may theoretically play an adjunct role in some thrombotic/CTEPH (chronic thromboembolic pulmonary hypertension) pathophysiology, but the trials and literature provided are not focused on pulmonary hypertension — this is a typical TxGNN high-score signal without corresponding evidence (a likely false positive)."

Both retrieved clinical trials (NOAC use in atrial fibrillation; cancer-associated thrombosis screening) and both retrieved publications (COVID-19 comorbidity therapy; clopidogrel adherence post-PCI) are only tangentially related to antiplatelet therapy in general and do not study prasugrel in pulmonary hypertension. The mechanistic hypothesis (antiplatelet effect in CTEPH) is biologically plausible in theory but currently unsupported by direct data.

Note on alternative candidates: Among the other 9 predicted indications in this evidence pack, migraine disorder (rank 2, score 99.88%) has comparatively stronger supporting evidence — an open-label pilot study and a retrospective cohort study specifically describing thienopyridine (clopidogrel/prasugrel class) use reducing migraine symptoms in patients with patent foramen ovale (PFO), reaching evidence level L3 / decision stage S1 (Research Question). This may warrant separate evaluation, though it is drug-class-level evidence rather than prasugrel-specific.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03993119	N/A	Completed	500	Observational cross-sectional study of NOAC management in elderly Spanish patients with non-valvular atrial fibrillation; no direct relevance to prasugrel or pulmonary hypertension (relevance grade C).
NCT04846556	N/A	Completed	300	Retrospective study on trial-eligibility for cancer-associated thrombosis (CARAVAGGIO-type population); does not involve prasugrel or pulmonary hypertension (relevance grade C).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21241206	2011	Cohort	Curr Med Res Opin	Factors associated with clopidogrel adherence in ACS patients post-PCI; prasugrel mentioned only as an alternative regimen, not studied in pulmonary hypertension.
34713782	2021	Observational/retrospective	Kardiologiia	ACTIV registry analysis of background cardiovascular therapy and COVID-19 outcomes; no specific data on prasugrel or pulmonary hypertension.

Norway Market Information

Prasugrel currently holds no marketing authorization in Norway (market_status: 未上市 / Not Marketed, total_licenses: 0). No product listings are available for review.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data were retrievable for this evaluation (DDI query_status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (pulmonary hypertension) has evidence level L5 — a TxGNN model score with no corresponding disease-specific clinical trials or literature. Combined with the drug's non-marketed status in Norway and a blocking data gap on the official package insert (warnings/contraindications), the candidate does not currently meet the threshold to proceed past initial screening (S0).

To proceed, the following is needed:

TFDA/manufacturer package insert (warnings and contraindications) — currently a blocking data gap (DG001)
Confirmed mechanism of action data from DrugBank or equivalent source (DG002)
Disease-specific (pulmonary hypertension, ideally CTEPH) preclinical or clinical evidence for prasugrel, rather than general antiplatelet-class literature
If pursuing the migraine/PFO signal (rank 2) instead, a prasugrel-specific trial or case series, since current evidence is at the thienopyridine drug-class level only
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.